XIFIN Innovation Drives Growth in Four Key Business Areas Amid COVID-19 Pandemic
Summary
This includes expansion into digital and genomic health, remote patient monitoring and oncology — while driving notable results for clients and providing unique insights into lab testing activity. The move also delivers the scalability customers need to meet the increased claim and payor requirements that follow expanded remote monitoring services. Currently, XIFIN supports 10 of the top 12 publicly traded laboratories in the US and saw growth in all its segments, including an upwards of 500 percent volume increase in Molecular in 2020. “The XIFIN RPM technology infrastructure, analytics and services have been an essential component in meeting our goals,” said Kevin Feeley, CFO, BioReference Laboratories, an OPKO Health company. The companys cloud-based technology facilitates connectivity and workflow automation for accessing and sharing clinical and financial diagnostic data, linking healthcare stakeholders in the delivery and reimbursement of care.